Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Why are young people getting cancer? a massive study aims to find out.

NCT ID NCT04955808

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in different racial and ethnic groups. Participants provide samples during surgery, and no direct treatment is given.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2017

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients undergoing surgery to remove tumor tissue

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with either: * Histologically confirmed invasive carcinoma or multiple myeloma OR * Clinical diagnosis of carcinoma or multiple myeloma OR * Suspected clinical diagnosis of multiple myeloma * Patients with one of following tumor types and age ranges: * Breast cancer diagnosis at ages 18-45 * Colon cancer diagnosis at ages 18-55 * Kidney cancer at diagnosis at ages 18-50 (American Indian or Alaska Native \[AIAN\] and non-Hispanic Whites \[NHW\] only) * Liver cancer diagnosis at ages 18-55 * Prostate cancer diagnosis at ages 18-55 * Multiple myeloma diagnosis at ages 18-50 * Patients whose tumor specimen was collected or will be collected during one of the following routine procedures: * Surgery to remove cancer OR * Routine biopsy procedures performed to confirm a histologic diagnosis OR * Routine biopsy procedure performed to obtain additional tumor material for routine prognostic or predictive biomarkers OR * Routine procedure to place a vascular access device prior for systemic therapy * Patients who have received no therapy for their cancer other than surgery, irrespective of stage * Collection of specimens from living patients: * Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol * Collection of specimens from deceased patients: * Banked tissue samples and/or banked biologic fluid specimens of deceased patients may be used as long as all samples or specimens are properly de- identified prior to submission * Sites must use the Central Institutional Review Board for the National Cancer Institute (NCI CIRB). Exclusion Criteria: * Patients who do not meet criteria for an early onset malignancy * Prior systemic therapy or radiation therapy for their malignancy * Tumor does not meet quality metrics * Patient refused consent for use of tissue for research activities included in the Early Onset Malignancies Initiative * A diagnosis of a synchronous invasive malignancy * Patients with a history of invasive cancer or hematologic malignancy in preceding 5 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Cancer Institute Division of Cancer Prevention

    Rockville, Maryland, 20850, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.